China Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%
MT Newswires Live
Aug 11
China's National Medical Products Administration accepted Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) application to market the drug toripalimab in combination with another drug developed by RemeGen (HKG:9995, SHA:688331), according to a Hong Kong bourse filing on Saturday.
During Monday's midday trade, Shanghai Junshi's Hong Kong shares slipped over 1%, while Shanghai shares fell less than 1%. RemeGen's shares dropped less than 3%.
The supplemental new drug application seeks to market toripalimab, with the trade name Tuoyi, in combination of RemeGen's disitamab vedotin as a treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.